As part of the weekly research here at The Acquirer’s Multiple we’re always interested in superinvestors who hold the same stocks that appear in our Acquirer’s Multiple Stock Screeners, based on their latest 13F’s. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks.
While doing this research we’ve also uncovered a number of stocks that superinvestors have sold, or reduced in their portfolios, according to their latest 13f’s. So we’re now providing a new weekly feature article called ‘One Stock Superinvestors Are Selling‘. This week we’ll take a look at:
Bristol-Myers Squibb Co (NYSE: BMY)
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
A quick look at the price chart below for Bristol-Myers Squibb shows us that the stock is up 28% in the past twelve months.
Superinvestors who sold, or reduced Bristol-Myers Squibb stock to their portfolios include:
(Superinvestor – remaining shares)
Jim Simons – 43,497,131 shares
Cliff Asness – 3,408,283 shares
Rich Pzena – 1,462,708 shares
Khan Brothers – 1,015,804 shares
Mario Gabelli – 224,577 shares
Ken Fisher – 172,283 shares
Jeremy Grantham – 77,291 shares
Lee Ainslie – 65,373 shares
Murray Stahl – 51,034 shares
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple: